2-amino methylpyridine | 1314913-09-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-amino methylpyridine
• 英文别名: 1,2-Dihydropyridin-2-ylmethanamine
• CAS: 1314913-09-1
• 化学式: C₆H₁₀N₂
• 分子量: 110.159
• InChiKey: RUWDAYICIPGZFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ((1S,2R,3S,4R)-4-[2-((R)-3-amino-pyrrolidin-1-yl)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-2,3-dihydroxy-cyclopentyl)-carbamic acid benzyl ester 、 2-amino methylpyridine 、 氯甲酸苯酯 在 三乙胺 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 为溶剂， 反应 2.0h， 生成 ((1S,2R,3S,4R)-4-{6-(2,2-diphenyl-ethylamino)-2-[(R)-3-(3-pyridin-2-ylmethyl-ureido)-pyrrolidin-1-yl]-purin-9-yl}-2,3-dihydroxy-cyclopentyl)-carbamic acid benzyl ester
  参考文献：
  名称：

  Organic Compounds

  摘要：

  化合物的公式（I）或其立体异构体或药用可接受的盐，以及它们的制备和用途作为药物，其中R1、R2和R3如本文所定义。

  公开号：

  US20100286126A1

文献信息

• HEPATITIS C INHIBITOR COMPOUNDS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2748167B1

  公开（公告）日：2017-03-01
• [EN] FUSED HETEROBICYCLO SUBSTITUTED PHENYL METABOTROPIC GLUTAMATE-5 MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR GLUTAMATE METABOTROPIQUE 5 (MGLUR5) DE PHENYLE SUBSTITUES PAR UN FRAGMENT HETEROBICYCLO FUSIONNE
  申请人：MERCK & CO INC

  公开号：WO2004024074A2

  公开（公告）日：2004-03-25

  Phenyl compounds substituted with a fused-heterobicyclo moiety, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, and panic, as well as in the treatment of pain and other diseases.
• [EN] FK228 ANALOGS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] ANALOGUES DE FK228 ET METHODES DE PRODUCTION ET D'UTILISATION DESDITS ANALOGUES
  申请人：WISCONSIN ALUMNI RES FOUND

  公开号：WO2005058298A2

  公开（公告）日：2005-06-30

  The present invention provides FK228 analogs and methods of making and using the same. Such analogs are potent inhibitors of histone deacetylase and, in certain embodiments, are capable of specifically targeting cancerous cells and tissues. In preferred embodiments, these analogs are characterized by a cyclic disulfide design.
• [EN] PHARMACEUTICAL COMBINATIONS OF A PKC INHIBITOR AND A C-MET RECEPTOR TYROSINE KINASE INHIBITOR<br/>[FR] COMBINAISONS PHARMACEUTIQUES D'UN INHIBITEUR DE LA PKC ET D'UN INHIBITEUR DU RÉCEPTEUR TYROSINE-KINASE C-MET
  申请人：NOVARTIS AG

  公开号：WO2014174478A1

  公开（公告）日：2014-10-30

  A pharmaceutical combination comprising (a) a protein kinase C (PKC) inhibitor, or a pharmaceutically acceptable salt thereof, and (b) at least one c-MET receptor tyrosine kinase inhibitor, or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
• [EN] GLS1 INHIBITORS FOR TREATING DISEASE<br/>[FR] INHIBITEURS DE LA GLS1 POUR LE TRAITEMENT DE MALADIES
  申请人：UNIV TEXAS

  公开号：WO2016004413A2

  公开（公告）日：2016-01-07

  Disclosed herein are compounds and compositions useful in the treatment of GLS1 mediated diseases, such as cancer, having the structure of Formula I. Methods of inhibition GLS1 activity in a human or animal subject are also provided.